Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 59 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: GL701 Clear all

Conditions: Breast Cancer
Interventions: polymorphism analysis, high performance liquid chromatography, laboratory biomarker analysis, radiomammography; Genetic · Other · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 180
States / cities: Augusta, Georgia • Aurora, Illinois • Bloomington, Illinois + 111 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Placebo Oral Tablet, Fluoxetine, DHEA, Fluoxetine and DHEA; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 50 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Vaginal Atrophy
Interventions: Placebo, DHEA (0.25%), DHEA (0.5%), DHEA (1.0%); Drug
Lead sponsor: EndoCeutics Inc.; Industry
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Cleveland, Ohio • Norfolk, Virginia

Conditions: Osteoporosis, Frailty
Interventions: DHEA, Yoga, Placebo, Aerobics; Dietary Supplement · Behavioral
Lead sponsor: National Aeronautics and Space Administration (NASA); Federal
Eligibility: 65 Years and older · Female only
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Breast Cancer, Gynecologic Cancer
Interventions: prasterone, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 280
States / cities: Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 185 more

Conditions: Primary Ovarian Insufficiency, Female Infertility Due to Diminished Ovarian Reserve
Interventions: Testosterone cream (0.5mg per gram), DHEA, Placebo; Drug · Dietary Supplement
Lead sponsor: Center for Human Reproduction; Other
Eligibility: 38 Years to 44 Years · Female only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 2
States / cities: New York, New York • Rochester, New York

Conditions: Breast Cancer
Interventions: DHEA, Surgical resection; Drug · Procedure
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Vaginal Atrophy
Interventions: Placebo, DHEA; Drug
Lead sponsor: EndoCeutics Inc.; Industry
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 24
States / cities: Montgomery, Alabama • Tucson, Arizona • Sacramento, California + 20 more

Conditions: Bacterial Vaginosis, Candidiasis, Urinary Tract Infections, Genitourinary Syndrome of Menopause, Lichen Sclerosus, Lichen Planus, Vulvodynia, Endometriosis, Ureaplasma Infections, Cancer, Desquamative Inflammatory Vaginitis
Interventions: Vaginal Swab Collection; Diagnostic Test
Lead sponsor: Vaginal Biome Science; Other
Eligibility: 18 Years to 89 Years · Female only
Enrollment: 3,250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 20
States / cities: Fullerton, California • Los Angeles, California • Pasadena, California + 16 more

Conditions: Posttraumatic Stress Disorder
Interventions: DHEA; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Substance Withdrawal Syndrome
Interventions: dehydroepiandrosterone (DHEA), pregnenolone, Placebo; Dietary Supplement · Drug
Lead sponsor: Jed E. Rose; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Durham, North Carolina • Raleigh, North Carolina

Conditions: Contraceptive Usage, Coagulation
Interventions: DHEA Oral Capsule, Placebo Oral Capsule; Dietary Supplement · Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Post-menopause, Pre-menopause, Sexual Function, Menopause, Vaginal Dryness, Painful Intercourse
Interventions: DHEA ovals, Estradiol 0.01% Vag Cream; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 40 Years to 90 Years · Female only
Enrollment: 324 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Healthy
Interventions: DHEA; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 60 Years and older
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Low Bone Mass, Osteoporosis, Postmenopausal
Interventions: DHEA, Placebo, Exercise; Other · Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 55 Years to 85 Years · Female only
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hyperandrogenism
Interventions: Dehydroepiandrosterone (DHEA), Placebo; Dietary Supplement · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Systemic Lupus Erythematosus
Interventions: Dehydroepiandrosterone (DHEA); Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Anal Carcinoma, Cervical Carcinoma, Malignant Female Reproductive System Neoplasm, Rectal Carcinoma, Vaginal Carcinoma, Vulvar Carcinoma
Interventions: Biospecimen Collection, Prasterone, Survey Administration; Procedure · Drug · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 50 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Aging, Obesity, Insulin Resistance
Interventions: DHEA; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 65 Years to 78 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Placebo Vaginal Insert, Prasterone 6.5 mg (0.50%) Vaginal Insert; Drug
Lead sponsor: EndoCeutics Inc.; Industry
Eligibility: 40 Years to 80 Years · Female only
Enrollment: 653 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 63
States / cities: Huntsville, Alabama • Mobile, Alabama • Tucson, Arizona + 53 more

Conditions: Crohn's Disease
Interventions: Dehydroepiandrosterone [DHEA]; Drug
Lead sponsor: Inflabloc Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 29
States / cities: Huntsville, Alabama • Anaheim, California • San Diego, California + 25 more

Conditions: Vaginal Atrophy
Interventions: Placebo, Prasterone (DHEA); Drug
Lead sponsor: EndoCeutics Inc.; Industry
Eligibility: 40 Years to 80 Years · Female only
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 24
States / cities: Montgomery, Alabama • Tucson, Arizona • Sacramento, California + 19 more

Conditions: Systemic Lupus Erythematosus
Interventions: Prasterone (GL701); Drug
Lead sponsor: Genelabs Technologies; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 21
States / cities: Tucson, Arizona • Los Angeles, California • Rancho Mirage, California + 18 more

Conditions: Infertility
Interventions: dehydroepiandrosterone; Dietary Supplement
Lead sponsor: Virginia Center for Reproductive Medicine; Other
Eligibility: 21 Years to 44 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Reston, Virginia

Search by objective public record fields.

Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer

The Effects of Fluoxetine and/or DHEA

Topical DHEA Against Vaginal Atrophy

Effects of DHEA/Exercise on Bone, Muscle and Balance

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

Effect of Testosterone Treatment on Embryo Quality

DHEA in Treating Women Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer

DHEA Against Vaginal Atrophy - 3-Month Efficacy Study

Vaginal Ecosystem and Network in the United States Study

Neurosteroids in PTSD - Biomarkers to Therapeutics

The Effects of One-Time Pregnenolone, Dehydroepiandrosterone (DHEA), or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers

How DHEA Supplements Affect Coagulation in Women Using Birth Control Pills

VEDA Study (DHEA vs Estradiol)

Biological Effects of Dehydroepiandrosterone (DHEA) in the Elderly

DHEA Augmentation of Musculoskeletal Adaptations to Exercise in Older Women

Effects of Androgen Administration on Inflammation in Normal Women

Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention

Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer

Biologic Effects of Dehydroepiandrosterone (DHEA) in Humans

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)

An Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Crohn's Disease

Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause

GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids

The Effect of DHEA on Markers of Ovarian Reserve in Women With Diminished Ovarian Reserve